Literature DB >> 11472078

Determination of free insulin-like growth factor-I in human serum: comparison of ultrafiltration and direct immunoradiometric assay.

J Frystyk1, P Ivarsen, R K Støving, R Dall, T Bek, C Hagen, H Ørskov.   

Abstract

Two fundamentally different methods are currently used for the determination of free insulin-like growth factor-I (IGF-I): ultrafiltration by centrifugation (UF) and direct immunoradiometric assay (IRMA). The aim was to evaluate a commercial IRMA (DSL, Webster, TX, USA) and to compare it with UF. In the IRMA it is recommended that samples be incubated for 2 h at 5;C. When comparing samples (n = 8) incubated for 1 and 2 h, levels increased by 27 +/- 5% (P< 0.0001). When incubating samples at 22;C instead of 5;C, levels increased by 192 +/- 32% (P< 0.0001). Addition of IGF-binding protein-1 (IGFBP-1) to normal sera (n = 6) dose-dependently decreased ultrafiltered free IGF-I only (P< 0.0007). Similarly, UF was more sensitive than IRMA to addition of IGFBP-2 (P< 0.05). In healthy subjects (n = 35) IRMA yielded 20% higher levels than UF (1.09 +/- 0.09 vs 0.91 +/- 0.12 microg/L; P< 0.0001). IRMA and UF yielded similar results in healthy subjects treated with IGF-I (n = 5) or growth hormone (n = 7) and in acromegalic patients (n = 6) before and after somatostatin analogue treatment. However, marked differences were observed in conditions with elevated IGFBP-1 and -2. In type-1 diabetics (n = 23) ultrafiltered free IGF-I was more reduced than IRMA free IGF-I (38 +/- 9 vs 76 +/- 7% of matched controls (n = 13); P< 0.0001). In patients with chronic renal failure (n = 25), IRMA free IGF-I was identical to control levels (n = 13), whereas ultrafiltered free IGF-I was decreased by 51 +/- 7% (P< 0.0001). Similarly, women with anorexia nervosa (n = 9) studied before and after weight gain showed significant changes in ultrafiltered free IGF-I only (P< 0.03). In conclusion, IRMA was not very robust with respect to variations in sample incubation and this may bias results. IRMA generally yielded higher levels than UF, in accordance with the knowledge that IRMA measures free plus readily dissociable IGF-I. IRMA was less affected than UF by added IGFBP-1 and -2, and reductions in free IGF-I were better revealed by UF than IRMA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11472078     DOI: 10.1054/ghir.2001.0197

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  7 in total

1.  Plasma ghrelin levels and malnutrition: a comparison of two etiologies.

Authors:  M Krsek; M Rosická; H Papezová; J Krízová; E Kotrlíková; M Haluz'k; V Justová; Z Lacinová; Z Jarkovská
Journal:  Eat Weight Disord       Date:  2003-09       Impact factor: 4.652

2.  Testosterone and estradiol regulate free insulin-like growth factor I (IGF-I), IGF binding protein 1 (IGFBP-1), and dimeric IGF-I/IGFBP-1 concentrations.

Authors:  Johannes D Veldhuis; Jan Frystyk; Ali Iranmanesh; Hans Ørskov
Journal:  J Clin Endocrinol Metab       Date:  2005-02-15       Impact factor: 5.958

Review 3.  IGF-I/IGFBP system: metabolism outline and physical exercise.

Authors:  R Gatti; E F De Palo; G Antonelli; P Spinella
Journal:  J Endocrinol Invest       Date:  2012-06-18       Impact factor: 4.256

4.  The insulin-like growth factor system: towards clinical applications.

Authors:  Leon A Bach
Journal:  Clin Biochem Rev       Date:  2004-08

Review 5.  Circulating free insulin-like growth-factor-I (IGF-I) levels should also be measured to estimate the IGF-I bioactivity.

Authors:  J A M J L Janssen; A J van der Lely; S W J Lamberts
Journal:  J Endocrinol Invest       Date:  2003-06       Impact factor: 4.256

6.  Serum Levels of Free Insulin-Like Growth Factor (IGF)-I in Normal Children.

Authors:  Atsuko Nimura; Noriyuki Katsumata; Toshiaki Tanaka
Journal:  Clin Pediatr Endocrinol       Date:  2004-07-07

Review 7.  Utility of free IGF-I measurements.

Authors:  Jan Frystyk
Journal:  Pituitary       Date:  2007       Impact factor: 3.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.